The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1438
Intranasal Naloxone for Treatment of Opioid Overdose
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The recent increase in deaths from heroin overdose in the US has led to renewed interest in the opioid antagonist naloxone, particularly in making it available as an intranasal spray to paramedics and possibly to relatives and close friends of heroin users. Intravenous (IV) administration is preferred, but peripheral venous access may be difficult to obtain in IV drug abusers, and exposure to their blood may be hazardous.

PHARMACOLOGY — Naloxone is a semisynthetic derivative of thebaine that is structurally similar to oxymorphone. It acts as a competitive antagonist at opioid receptors in the brain. Unlike other opioid antagonists, it has no opioid agonist effects. In patients with opioid overdose, naloxone begins to reverse sedation, respiratory depression, and hypotension within 1-2 minutes after IV administration and 2-5 minutes after intramuscular (IM) or subcutaneous (SC) administration. It has a half-life of 30-80 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Intranasal Naloxone for Treatment of Opioid Overdose
Article code: 1438b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian